Middlebrook Pharmaceuticals discovered in 2000 that bacteria exposed to antibiotics in front-loaded, sequential bursts, or pulses, are killed more efficiently than those exposed to standard antibiotic treatment regimens. The company went on to develop novel anti-infective pulsatile drug products that take advantage of this discovery.

Middlebrook is applying their technology to drugs that may have lost their effectiveness in previous applications. The advantages of pulse therapy are: once-a-day formulation, lower dosages, shorter duration of therapy, reduced side effects, reduced incidence of resistance, combination products with superior efficacy over either product alone, and improved pediatric and geriatric dosages.

The $100M investment in Middlebrook should be exciting for investors. However, some Middlebrook investors were hoping for an outright buyout at $6 to $8 dollars a share by a larger pharmaceutical. This investment shows that the company is viable, and that a serious investment company such as Equity Group Investments, LLC would not have moved

Taplmmune, Inc. (TPIM.OB) is a developer of new innovative therapeutics and vaccines in the oncology and infectious disease areas. The company’s therapeutics and vaccines are based on technologies that utilize transporters associated with Antigen Processing (TAP). TAP therapy offers improvements in efficacy as well as reduced side effects and a boost in body defenses.

Teplmmune’s TAP cancer vaccine primarily moves antigens to the surface of cells and restores TAP proteins and the immune system’s ability to recognize and destroy cancer cells. The TAP molecule has also shown abilities to enhance the potency of vaccines against infectious diseases.

Taplmmune’s TAP has already been through clinical studies and has proven several forms of cancer that are deficient to the vaccine. Some cancers deficient to the vaccine include melanoma, colon, cervical, lung, prostate, breast and ovarian. The company began their preclinical testing of TAP in 2007, and is currently

In last week’s strategy article I did some basic analysis on the MACD; a trend indicator. In this week’s article I took a look at stochastics; a momentum indicator. However, unlike the traditional overbought/oversold triggers associated with using stochastics I have opted to use a cross of the mid-line (50) with a base fast stochastic setting of [39,1,1]. I couldn’t test for the optimum [39,1,3] using the %K smooth as a trade trigger, so the generated signals were not as good as the basic slow stochastic signal I normally use (see chart for differences in the quality of the signals), but it did give an indication of the efficacy of this strategy.

Test period: A complete bull-bear cycle defined by the S&P …